Meta-Analysis A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett’s Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease

Barrett’s esophagus is associated with reflux disease and substantially increases the risk of esophageal adenocarcinoma. The authors undertook a systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease (ERD), and nonerosive reflux disease (non-ERD) to compare these results with the sex ratio for esophageal adenocarcinoma. MEDLINE (US National Library of Medicine, Bethesda, Maryland) (1966–2004) and EMBASE (Reed Elsevier PLC, Amsterdam, Netherlands) (1980–2004) were searched for rele-vant citations with a highly sensitive search strategy. Studies to be included required a sample size of 50 or more patients and consecutive recruitment at an institute accessible by all. Stata, version 8.2, software (StataCorp LP, College Station, Texas) was used to conduct random effects meta-analyses. Excess heterogeneity was investigated by meta-regression. The Barrett’s esophagus meta-analysis gave an overall pooled male/female sex ratio of 1.96/1 (95% confidence interval (CI): 1.77, 2.17/1). For ERD, the pooled male/female sex ratio was 1.57/1 (95% CI: 1.40, 1.76/1) and, for non-ERD, 0.72/1 (95% CI: 0.62, 0.84/1). All of these estimates were associated with substantial heterogeneity ( I 2 ¼ 81.1%, 92.7%, and 88.8%, respectively). The meta-analysis estimates for ERD and Barrett’s esophagus, while showing an excess of males, are substantially lower than similar estimates for esophageal adenocarcinoma. It is important to establish why male Barrett’s esophagus and ERD patients are at increased risk of malignancy compared with females.

[1]  P. Vestergaard,et al.  Oesophageal disease revealed by endoscopy in 1,000 patients referred primarily for gastroscopy. , 2009, Acta medica Scandinavica.

[2]  D. Forman,et al.  Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. , 2005, American journal of epidemiology.

[3]  E. Quigley Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? , 2004, Best practice & research. Clinical gastroenterology.

[4]  M. Solaymani-Dodaran,et al.  Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux , 2004, Gut.

[5]  P. Malfertheiner,et al.  Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. , 2004, Journal of clinical epidemiology.

[6]  F. Pace,et al.  Gastroesophageal Reflux Disease: A Typical Spectrum Disease (A New Conceptual Framework is Not Needed) , 2004, American Journal of Gastroenterology.

[7]  R. Sampliner,et al.  Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  R. Loffeld,et al.  Rising Incidence of Reflux Oesophagitis in Patients Undergoing Upper Gastrointestinal Endoscopy , 2004, Digestion.

[9]  V. Savarino,et al.  Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non‐erosive reflux disease , 2003, Alimentary pharmacology & therapeutics.

[10]  P. I. Reed,et al.  Characteristics and regional variations of patients with Barrett's oesophagus in the UK , 2003, European journal of gastroenterology & hepatology.

[11]  P. Malfertheiner,et al.  Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative , 2003, Alimentary pharmacology & therapeutics.

[12]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[13]  Christopher P. Wild,et al.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions , 2003, Nature Reviews Cancer.

[14]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[15]  W. Wong,et al.  Prevalence, clinical spectrum and health care utilization of gastro‐oesophageal reflux disease in a Chinese population: a population‐based study , 2003, Alimentary pharmacology & therapeutics.

[16]  A. Gavin,et al.  Mortality in Barrett’s oesophagus: results from a population based study , 2003, Gut.

[17]  P. Malfertheiner,et al.  Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study , 2003, Alimentary pharmacology & therapeutics.

[18]  A. Barkun,et al.  The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study , 2003, Alimentary pharmacology & therapeutics.

[19]  A. Clarke,et al.  Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma , 2003, Journal of gastroenterology and hepatology.

[20]  A. Damiano,et al.  Reductions in Symptom Distress Reported by Patients with Moderately Severe, Nonerosive Gastroesophageal Reflux Disease Treated with Rabeprazole , 2003, Digestive Diseases and Sciences.

[21]  D. Schilling,et al.  Natural course of erosive reflux disease: Results of a prospective study with a mean follow up of 6 years , 2003 .

[22]  J. Soares,et al.  Risk of neoplastic progression in Barrett's esophagus: Data from a prospective surveillance program in Portugal , 2003 .

[23]  J. Dillon,et al.  Gender differences in the epidemiology of GORD , 2003 .

[24]  A. Ootani,et al.  Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. , 2003, Journal of gastroenterology.

[25]  P. Parrilla,et al.  Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus , 2003, Annals of surgery.

[26]  D. Corley,et al.  Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States , 2002, Cancer.

[27]  I. Kunnamo,et al.  The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants , 2002, American Journal of Gastroenterology.

[28]  G. Triadafilopoulos,et al.  Prevalence of Barrett's esophagus in asymptomatic individuals. , 2002, Gastroenterology.

[29]  R. Fass,et al.  Gastroesophageal reflux disease—should we adopt a new conceptual framework? , 2002, American Journal of Gastroenterology.

[30]  V. Moreno,et al.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.

[31]  W. Orr,et al.  Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial , 2002, American Journal of Gastroenterology.

[32]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[33]  R. Hegedus,et al.  Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis , 2002, Alimentary pharmacology & therapeutics.

[34]  J. Devière,et al.  Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources , 2002, European journal of gastroenterology & hepatology.

[35]  G. Lapertosa,et al.  Risk factors for Barrett's esophagus: A case‐control study , 2002, International journal of cancer.

[36]  H. El‐Serag,et al.  Risk Factors for the Severity of Erosive Esophagitis in Helicobacter pylori -Negative Patients with Gastroesophageal Reflux Disease , 2002, Scandinavian journal of gastroenterology.

[37]  J. Lagergren,et al.  Body Mass and Reflux Oesophagitis: an Oestrogen-dependent Association? , 2002, Scandinavian journal of gastroenterology.

[38]  J. Peters,et al.  Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. , 2001, Archives of surgery.

[39]  R. Mittal,et al.  Sustained esophageal contraction: a motor correlate of heartburn symptom. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[40]  C. Gutschow,et al.  Demographic variations in the rising incidence of esophageal adenocarcinoma in white males , 2001, Cancer.

[41]  V. Eckardt,et al.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. , 2001, The American journal of medicine.

[42]  Y. Jeen,et al.  Prevalence of endoscopic reflux esophagitis among Koreans , 2001, Journal of gastroenterology and hepatology.

[43]  L. Melton,et al.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota , 2001, Gut.

[44]  R. Fass,et al.  Nonerosive Reflux Disease— Current Concepts And Dilemmas , 2001, American Journal of Gastroenterology.

[45]  T. Kennedy,et al.  The prevalence of gastro‐oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms , 2000, Alimentary pharmacology & therapeutics.

[46]  R. Playford,et al.  Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study , 2000, BMJ : British Medical Journal.

[47]  D. Forman,et al.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[48]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[49]  J. Richter,et al.  Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. , 2000, Archives of internal medicine.

[50]  P. Kahrilas,et al.  Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. , 2000, Archives of internal medicine.

[51]  B. Reid,et al.  Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.

[52]  A. Csendes,et al.  Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[53]  J. Mecklin,et al.  Gastroesophageal Reflux Disease: Prevalence, Clinical, Endoscopic and Histopathological Findings in 1,128 Consecutive Patients Referred for Endoscopy due to Dyspeptic and Reflux Symptoms , 2000, Digestion.

[54]  R. Stanton,et al.  Heartburn: Community perceptions , 2000, Journal of gastroenterology and hepatology.

[55]  T. Shimosegawa,et al.  Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis , 1999, American Journal of Gastroenterology.

[56]  J. Hyams Functional gastrointestinal disorders. , 1999, Current opinion in pediatrics.

[57]  J. Wilson,et al.  Functional esophageal disorders , 1999, Gut.

[58]  G. Falk,et al.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.

[59]  P. Malfertheiner,et al.  Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. , 1999, Gastroenterology.

[60]  S. I. Lee,et al.  Reflux esophagitis and its relationship to hiatal hernia. , 1999, Journal of Korean medical science.

[61]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[62]  B. Naliboff,et al.  Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. , 1998, Gastroenterology.

[63]  P. Malfertheiner,et al.  The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case‐control study , 1998, European journal of gastroenterology & hepatology.

[64]  L. Lundell,et al.  Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. , 1997, Scandinavian journal of gastroenterology.

[65]  M. Helfand,et al.  Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. , 1997, The American journal of gastroenterology.

[66]  R. Sampliner,et al.  Erosive Esophagitis and Barrett's Esophagus in Taiwan (A Higher Frequency than Expected) , 1997, Digestive Diseases and Sciences.

[67]  H. Smart,et al.  Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.

[68]  A. Axon,et al.  Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis , 1996, Alimentary pharmacology & therapeutics.

[69]  R. Goyal,et al.  The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. , 1996, Gastroenterology.

[70]  J. Galmiche,et al.  Oesophageal sensitivity to acid in patients with non-cardiac chest pain: is the oesophagus hypersensitive? , 1995, European journal of gastroenterology & hepatology.

[71]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[72]  P Laippala,et al.  Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. , 1995, Annals of medicine.

[73]  O. Nyrén,et al.  The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. , 1994, Scandinavian journal of gastroenterology.

[74]  Nicholas J. Talley,et al.  U. S. Householder survey of functional gastrointestinal disorders , 1993, Digestive Diseases and Sciences.

[75]  L. Lööf,et al.  The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. , 1993, Scandinavian journal of gastroenterology.

[76]  A. Csendes,et al.  Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis. , 1993, Gut.

[77]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[78]  F. Ellis,et al.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.

[79]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[80]  D J Ballard,et al.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. , 1990, Gastroenterology.

[81]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[82]  B. Cooper,et al.  Barrett's oesophagus: a clinical study of 52 patients. , 1987, The Quarterly journal of medicine.

[83]  A. Blum,et al.  Healing and relapse of reflux esophagitis during treatment with ranitidine. , 1986, Gastroenterology.

[84]  W. C. Watson,et al.  Management of adenocarcinoma in a columnar-lined esophagus. , 1985, The Annals of thoracic surgery.

[85]  D. Castell,et al.  Symptomatic gastroesophageal reflux: Incidence and precipitating factors , 1976, The American Journal of Digestive Diseases.

[86]  A. Csendes,et al.  Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. , 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[87]  A. Garrido Serrano,et al.  Clinical features and endoscopic progression of gastroesophageal reflux disease. , 2003, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[88]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.

[89]  R. Willén,et al.  Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. , 2000, Scandinavian journal of gastroenterology.

[90]  P. Kahrilas,et al.  Esophageal sensitivity and symptom perception in gastroesophageal reflux disease , 1999, Current gastroenterology reports.

[91]  M. Vieth,et al.  Short Barrett: prevalence and risk factors. , 1999, Scandinavian journal of gastroenterology.

[92]  R. Mcfarland,et al.  Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. , 1998, Scandinavian journal of gastroenterology.

[93]  Stephen J. Sharp,et al.  Meta-analysis regression , 1998 .

[94]  R. Sandler,et al.  The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. , 1997, The American journal of gastroenterology.

[95]  A. Csendes,et al.  Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. , 1997, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[96]  T. Venables,et al.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. , 1997, Scandinavian journal of gastroenterology.

[97]  J. Y. Kang,et al.  Low frequency of endoscopic esophagitis in Asian patients. , 1993, Journal of clinical gastroenterology.